Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Scientist Explains Prostate Cancer Vaccine

January 26, 2010

Dr. Philip Kantoff explains the findings from a randomized phase II study of PROSTVAC-VF vaccine. The study found that patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine. Credit: Chris Ingalls